BACKGROUND: Dementia must be diagnosed accurately and early in the disease course to allow pathology-specific treatments to be effective. Dementia with Lewy bodies (DLB) is often misdiagnosed as Alzheimer's disease (AD), especially at the prodromal stage. OBJECTIVE: To compare the clinical and neuropsychological profiles of Mild Cognitive Impairment (MCI) patients who, at follow-up, progressed to AD (retrospectively AD-MCI) or DLB (retrospectively DLB-MCI) or remained MCI. METHODS: This longitudinal study used an unselected sample from a memory clinic database. A total of 1,848 new patients were seen at the memory clinic between 1994-2015. Of these, 560 patients (30%) had an initial diagnosis of MCI and were considered for the study. Inclusion criteria were patients who had a diagnosis of MCI at initial assessment and a minimum of 12 months' follow-up. RESULTS: Of the 429 MCI patients with follow-up data, 164 (38%) remained MCI, 107 (25%) progressed to AD, and 21 (5%) progressed to DLB. The remainder progressed to alternative diagnoses. At baseline, DLB-MCI patients performed significantly worse on visuospatial function and letter fluency tests than both AD-MCI and stable-MCI groups, and better on episodic memory tests than the AD-MCI group. At baseline, DLB-MCI patients had a significantly higher mean UPDRS score and were more likely to have REM sleep behavior disorder and fluctuating cognition. CONCLUSION: DLB-MCI patients have a specific cognitive and neuropsychiatric profile which should alert clinicians to the possibility of prodromal DLB. This is relevant when considered in the context of early disease-specific therapy.
BACKGROUND:Dementia must be diagnosed accurately and early in the disease course to allow pathology-specific treatments to be effective. Dementia with Lewy bodies (DLB) is often misdiagnosed as Alzheimer's disease (AD), especially at the prodromal stage. OBJECTIVE: To compare the clinical and neuropsychological profiles of Mild Cognitive Impairment (MCI)patients who, at follow-up, progressed to AD (retrospectively AD-MCI) or DLB (retrospectively DLB-MCI) or remained MCI. METHODS: This longitudinal study used an unselected sample from a memory clinic database. A total of 1,848 new patients were seen at the memory clinic between 1994-2015. Of these, 560 patients (30%) had an initial diagnosis of MCI and were considered for the study. Inclusion criteria were patients who had a diagnosis of MCI at initial assessment and a minimum of 12 months' follow-up. RESULTS: Of the 429 MCI patients with follow-up data, 164 (38%) remained MCI, 107 (25%) progressed to AD, and 21 (5%) progressed to DLB. The remainder progressed to alternative diagnoses. At baseline, DLB-MCI patients performed significantly worse on visuospatial function and letter fluency tests than both AD-MCI and stable-MCI groups, and better on episodic memory tests than the AD-MCI group. At baseline, DLB-MCI patients had a significantly higher mean UPDRS score and were more likely to have REM sleep behavior disorder and fluctuating cognition. CONCLUSION: DLB-MCI patients have a specific cognitive and neuropsychiatric profile which should alert clinicians to the possibility of prodromal DLB. This is relevant when considered in the context of early disease-specific therapy.
Authors: Margaret Wiggins; Franchesca Arias; Richard D Urman; Deborah C Richman; Bobbie Jean Sweitzer; Angela F Edwards; Melissa J Armstrong; Anita Chopra; David J Libon; Catherine Price Journal: Perioper Care Oper Room Manag Date: 2020-02-05
Authors: Sarah Payne; Jane B Shofer; Andrew Shutes-David; Ge Li; Adrienne Jankowski; Pamela Dean; Debby Tsuang Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Christoph Mueller; Gayan Perera; Anto P Rajkumar; Manorama Bhattarai; Annabel Price; John T O'Brien; Clive Ballard; Robert Stewart; Dag Aarsland Journal: Alzheimers Dement (Amst) Date: 2017-12-27
Authors: Estrella Morenas-Rodríguez; Daniel Alcolea; Marc Suárez-Calvet; Laia Muñoz-Llahuna; Eduard Vilaplana; Isabel Sala; Andrea Subirana; Marta Querol-Vilaseca; María Carmona-Iragui; Ignacio Illán-Gala; Roser Ribosa-Nogué; Rafael Blesa; Christian Haass; Juan Fortea; Alberto Lleó Journal: Sci Rep Date: 2019-05-24 Impact factor: 4.379
Authors: Kathryn A Wyman-Chick; Lauren R O'Keefe; Daniel Weintraub; Melissa J Armstrong; Michael Rosenbloom; Phillip K Martin; Terry R Barclay; Matthew J Barrett Journal: J Geriatr Psychiatry Neurol Date: 2021-06-11 Impact factor: 2.718
Authors: Marleen van de Beek; Inger van Steenoven; Jessica J van der Zande; Frederik Barkhof; Charlotte E Teunissen; Wiesje M van der Flier; Afina W Lemstra Journal: Mov Disord Date: 2020-02-11 Impact factor: 10.338